April 29 - 30, 2019
Sheraton Austin Hotel at the Capitol
Abstract submission deadline: Wednesday, February 6
Advance registration deadline: Thursday, March 21
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians. Credit Designation Statement
AACR has designated this live activity for a maximum of 12.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Tuesday, June 4, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on this website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Head and neck cancers represent a diverse collection of rare to common neoplasms that arise from all three germ cell layers within the head and neck region. Head and Neck Squamous Cell Carcinoma (HNSCC) is one of the six most common cancers worldwide, and includes cancers arising from the oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, and paranasal sinuses. There is some regional variation in the distribution of sites represented related to social and environmental influences. In western countries, the transmission of high risk human papilloma virus (HPV) has been linked with a striking increase in the incidence of cancers of the oropharynx, particularly in the tonsils and the tongue base, while a decline in smoking has been associated with falling incidences of oral and laryngeal cancers. The increase in HPV+ HNSCC, which is highly responsive to cytotoxic treatments combined with recent developments in surgery, radiation delivery, and systemic therapies has led to improved survival rates for patients with this subset of tumors. These encouraging trends in response and survival have in turn led to an emphasis on improved selection of patients for specific treatments in order to maintain excellent disease control and to decrease the short and longer-term morbidity related to cancer treatment. In contrast, much less progress has been made in the treatment of HPV- HNSCC, which still accounts for the majority of HNSCC cases and has a dismal response rate.
There has been recent progress made in understanding the genomics, signaling pathways and immunology of HNSCC that is beginning to influence the selection of therapy for these diverse cancers. It is our hope that this meeting will bring together experts and trainees to share data regarding their discoveries in head and neck cancers and to develop new collaborations that can enhance and stimulate new research.
After participating in this CME activity, physicians should be able to:
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by Professional Educational grants will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or email@example.com.